Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregor Verhoef

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
Haematologica|May 12, 2018
A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapyMarek Trnĕný, Gregor Verhoef, Martin Js Dyer, et al.
Blood|January 28, 2010
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 studyBob Löwenberg, Joachim Beck, Carlos Graux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2016
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II TrialRalf U Trappe, Daan Dierickx, Heiner Zimmermann, et al.
Transplantation|May 15, 2018
Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 TrialsHeiner Zimmermann, Nina Babel, Daan Dierickx, et al.
Blood|October 24, 2002
High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patientsSahar Barjesteh van Waalwijk van Doorn-Khosrovani, Claudia Erpelinck, Wim L J van Putten, et al.
The New England Journal of Medicine|March 15, 2003
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaStephen G O'Brien, François Guilhot, Richard A Larson, et al.
Haematologica|May 20, 2017
Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinibStein-Erik Gullaksen, Jørn Skavland, Sonia Gavasso, et al.
Blood|May 19, 2010
Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma GroupMarta Salido, Cristina Baró, David Oscier, et al.
Acta Clinica Belgica|February 23, 2017
Results from the Belgian mantle cell lymphoma registryVibeke Vergote, Ann Janssens, Marc André, et al.
The New England Journal of Medicine|March 28, 2003
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndromeJan Cools, Daniel J DeAngelo, Jason Gotlib, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
Haematologica|May 12, 2018
A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapyMarek Trnĕný, Gregor Verhoef, Martin Js Dyer, et al.
Blood|January 28, 2010
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 studyBob Löwenberg, Joachim Beck, Carlos Graux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2016
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II TrialRalf U Trappe, Daan Dierickx, Heiner Zimmermann, et al.
Transplantation|May 15, 2018
Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 TrialsHeiner Zimmermann, Nina Babel, Daan Dierickx, et al.
Blood|October 24, 2002
High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patientsSahar Barjesteh van Waalwijk van Doorn-Khosrovani, Claudia Erpelinck, Wim L J van Putten, et al.
The New England Journal of Medicine|March 15, 2003
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaStephen G O'Brien, François Guilhot, Richard A Larson, et al.
Haematologica|May 20, 2017
Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinibStein-Erik Gullaksen, Jørn Skavland, Sonia Gavasso, et al.
Blood|May 19, 2010
Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma GroupMarta Salido, Cristina Baró, David Oscier, et al.
Acta Clinica Belgica|February 23, 2017
Results from the Belgian mantle cell lymphoma registryVibeke Vergote, Ann Janssens, Marc André, et al.
The New England Journal of Medicine|March 28, 2003
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndromeJan Cools, Daniel J DeAngelo, Jason Gotlib, et al.
Pageof 10